Inflammatory bowel disease (IBD) affects over 1.5 million US citizens, and the incidence of disease is rising.1 While the pathogenesis of IBD is multifactorial, it is well established that the immune system plays a substantial role in the development of disease.2 Targeting specific immune mediators by biologics has become an increasingly widely used and effective treatment option.3 Among available biologics, antibodies specific for blockade of tumor necrosis factor (TNF) are currently the most commonly used therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.